Published in Heart on July 01, 1997
Interrelationships among noninvasive measures of postischemic macro- and microvascular reactivity. J Appl Physiol (1985) (2008) 2.29
Handgrip exercise increases postocclusion hyperaemic brachial artery dilatation. Heart (1999) 0.76
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (1992) 11.50
Flow-mediated endothelial mechanotransduction. Physiol Rev (1995) 10.13
On the local reactions of the arterial wall to changes of internal pressure. J Physiol (1902) 9.36
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 4.59
Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation (1993) 4.53
Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol (1994) 3.71
Single stretch-activated ion channels in vascular endothelial cells as mechanotransducers? Nature (1987) 3.37
Haemodynamic shear stress activates a K+ current in vascular endothelial cells. Nature (1988) 3.12
Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension (1986) 2.96
Endothelium-dependent, flow-induced dilation of isolated coronary arterioles. Am J Physiol (1990) 2.16
Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol (1995) 1.60
Non-invasive measurement of endothelial function: effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart (1997) 1.38
EDRF-mediated shear-induced dilation opposes myogenic vasoconstriction in small rabbit arteries. Am J Physiol (1991) 1.23
Flow-dependent coronary artery dilatation in humans. Circulation (1989) 1.16
Flow-dependent dilation in a resistance artery still occurs after endothelium removal. Circ Res (1988) 0.89
Blood-flow sensing by anionic biopolymers. J Auton Nerv Syst (1996) 0.85
Systemic vascular adaptation to increases in blood volume: the role of the blood-vessel wall. Nephrol Dial Transplant (1996) 0.79
Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet (1992) 4.64
A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ (1999) 3.23
Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet (1997) 2.66
What is the optimal age for starting lipid lowering treatment? A mathematical model. BMJ (2000) 2.65
Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension (1995) 2.54
Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation (2000) 2.27
Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest (1992) 2.26
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res (2001) 2.02
Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J (1999) 2.00
Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens (1992) 1.77
Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res (1994) 1.74
Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res (1999) 1.69
Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol (1996) 1.68
Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation (1997) 1.61
Measurement of nitrite and nitrate levels in plasma and urine--what does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertens (1998) 1.51
Combined coronary artery bypass grafting and abdominal aortic aneurysm repair. Am J Surg (1998) 1.49
Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation (2001) 1.49
Forearm blood flow responses to a nitric oxide synthase inhibitor in patients with treated essential hypertension. Cardiovasc Res (1994) 1.43
Lessons learned from a 6-year clinical experience with superior vena cava Greenfield filters. J Vasc Surg (2000) 1.41
Taking risks: primary prevention of cardiovascular events. N Z Med J (2001) 1.38
Endothelial dysfunction in cardiovascular disease. Hosp Med (1998) 1.38
Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res (1993) 1.35
Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk. Kidney Int (2006) 1.30
Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol (1994) 1.28
Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol (2001) 1.28
Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int (1997) 1.28
Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke (1998) 1.26
Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke (2004) 1.25
Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) (2004) 1.24
Nitric oxide and cardiovascular control. Exp Physiol (1993) 1.21
Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics (2000) 1.20
Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int (1994) 1.20
Second messenger role for NO widens to nervous and immune systems. Trends Pharmacol Sci (1989) 1.17
Effect of inhibition of nitric oxide synthase on dynamic cerebral autoregulation in humans. Clin Sci (Lond) (2000) 1.12
Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet (2001) 1.12
Direct measurement of nitric oxide in human beings. Lancet (1995) 1.11
Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res (1996) 1.11
Biochemical characterization of S-nitrosohemoglobin. Mechanisms underlying synthesis, no release, and biological activity. J Biol Chem (1999) 1.09
Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation (2000) 1.08
Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol (1995) 1.07
Lifetime risk of developing coronary heart disease. Lancet (1999) 1.04
Changes in the practice of angioaccess surgery: impact of dialysis outcome and quality initiative recommendations. J Vasc Surg (2000) 1.03
Nitric oxide takes centre-stage with newly defined roles. Trends Pharmacol Sci (1992) 1.01
Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet (1993) 1.01
Drugs and the fetus. BMJ (1996) 1.00
Positive association of tyrosine hydroxylase microsatellite marker to essential hypertension. Hypertension (1998) 1.00
Effect of stress management on blood pressure in mild primary hypertension. BMJ (1993) 1.00
Drug therapy for coronary heart disease: the Sheffield table. Lancet (1998) 0.99
Local venous responses to endotoxin in humans. Circulation (1996) 0.98
Nitric oxide and vascular responses in Type I diabetes. Diabetologia (2000) 0.97
Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. J Am Coll Cardiol (2001) 0.97
Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol (1994) 0.96
Positive inotropic effects of NO donors in isolated guinea-pig and human cardiomyocytes independent of NO species and cyclic nucleotides. Cardiovasc Res (2000) 0.96
Periodontal therapy: a novel non-drug-induced experimental model to study human inflammation. J Periodontal Res (2004) 0.96
Nitric oxide and blood pressure: effects of nitric oxide deficiency. Curr Opin Nephrol Hypertens (1996) 0.95
Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant (1996) 0.95
Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery. J Pharmacol Exp Ther (1995) 0.95
Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol (2005) 0.95
Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension (2001) 0.95
Bayesian methods for meta-analysis of causal relationships estimated using genetic instrumental variables. Stat Med (2010) 0.93
Plasma nitrogen oxides and blood lactate concentrations in Ghanaian children with malaria. Trans R Soc Trop Med Hyg (1997) 0.93
Dilator actions of arginine in human peripheral vasculature. Clin Sci (Lond) (1991) 0.93
Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun (2003) 0.92
Endothelial nitric oxide in humans in health and disease. Int J Exp Pathol (1999) 0.92
Differential effect of three cyclooxygenase inhibitors on human cerebral blood flow velocity and carbon dioxide reactivity. Stroke (1994) 0.91
Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel physiology and pathophysiology. Br J Pharmacol (1999) 0.91
The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model. Health Technol Assess (2010) 0.91
Effects of cytokines on nitric oxide pathways in human vasculature. Curr Opin Nephrol Hypertens (1999) 0.89
Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS. Cardiovasc Res (1999) 0.89
Endothelium-dependent sensory NANC vasodilatation: involvement of ATP, CGRP and a possible NO store. Br J Pharmacol (1998) 0.89
Nitric oxide in essential and renal hypertension. J Am Soc Nephrol (1994) 0.89
Endothelium-derived relaxing factor is an endogenous vasodilator in man. Br J Pharmacol (1989) 0.88
Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol (1997) 0.88
Carotid surgery without external carotid endarterectomy: a 6-year clinical experience with 1027 cases. Eur J Vasc Endovasc Surg (2003) 0.88
Identification of microbial dimethylarginine dimethylaminohydrolase enzymes. Mol Microbiol (1999) 0.87
Procedures for the outpatient management of patients with deep venous thrombosis. Clin Lab Haematol (2005) 0.87
Effect of local inhibition of nitric oxide synthesis on forearm blood flow and dorsal hand vein size in patients with alcoholic cirrhosis. Clin Sci (Lond) (1994) 0.87
Biphasic response to acetylcholine in human veins in vivo: the role of the endothelium. Clin Sci (Lond) (1990) 0.87
Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women. J Clin Endocrinol Metab (2001) 0.87
The effect of the nitric oxide donor glyceryl trinitrate on global and regional cerebral blood flow in man. J Neurol Sci (2000) 0.87
Routine preoperative carotid duplex scanning in patients undergoing open heart surgery: is it worthwhile? Ann Vasc Surg (2001) 0.86
Physiological importance of nitric oxide. BMJ (1991) 0.86
Saphenous vein thrombophlebitis (SVT): a deceptively benign disease. J Vasc Surg (1998) 0.86
Intracellular localization of dimethylarginine dimethylaminohydrolase overexpressed in an endothelial cell line. Acta Physiol Scand (2000) 0.85
Expression of molecular mediators of apoptosis and their role in the pathogenesis of lower-extremity varicose veins. J Vasc Surg (2001) 0.85
Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effect? Clin Sci (Lond) (1995) 0.85
Nitric oxide 9 years on. J R Soc Med (1996) 0.85
Vasodilatation to arachidonic acid in humans. An insight into endogenous prostanoids and effects of aspirin. Circulation (1995) 0.85
Carotid Artery Stump Pressure (CASP) in 1135 consecutive endarterectomies under general anesthesia: an old method that survived the test of times. J Cardiovasc Surg (Torino) (2007) 0.85
The effect of the nitric oxide synthase inhibitor L-NMMA on basal CBF and vasoneuronal coupling in man: a PET study. J Cereb Blood Flow Metab (1999) 0.85
Endogenous inhibitors of nitric oxide synthesis: how important are they? Exp Nephrol (1998) 0.84
Glycine preserves function and decreases necrosis in skeletal muscle undergoing ischemia and reperfusion injury. Surgery (2001) 0.84
Tyrosine nitration in blood vessels occurs with increasing nitric oxide concentration. Br J Pharmacol (1999) 0.84
Evidence for functional responses to sensory nerve stimulation of rat small mesenteric veins. J Pharmacol Exp Ther (1997) 0.83
Interaction between sympathetic and sensory nerves in rat small arteries: involvement of nitric oxide. Am J Physiol (1996) 0.83
Prospective study of mortality associated with chronic lung disease and smoking in Papua New Guinea. Int J Epidemiol (1988) 0.82